Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Lincoln National Corp

Lincoln National Corp raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 53.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,060 shares of the pharmaceutical company’s stock after acquiring an additional 714 shares during the period. Lincoln National Corp’s holdings in Vertex Pharmaceuticals were worth $838,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Arlington Trust Co LLC lifted its stake in shares of Vertex Pharmaceuticals by 97.1% during the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 33 shares during the period. Fortitude Family Office LLC acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $30,000. Baystate Wealth Management LLC lifted its stake in shares of Vertex Pharmaceuticals by 49.0% during the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after buying an additional 25 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth $25,000. Finally, NBC Securities Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth $34,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Trading Up 0.0 %

Shares of NASDAQ VRTX opened at $418.99 on Friday. Vertex Pharmaceuticals Incorporated has a twelve month low of $320.01 and a twelve month high of $448.40. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02. The stock has a fifty day simple moving average of $407.86 and a 200-day simple moving average of $400.88. The stock has a market capitalization of $108.29 billion, a PE ratio of 30.16, a PEG ratio of 1.89 and a beta of 0.39.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 EPS for the quarter, topping the consensus estimate of $3.66 by $1.10. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The firm had revenue of $2.69 billion during the quarter, compared to analysts’ expectations of $2.58 billion. During the same period in the previous year, the firm posted $2.67 EPS. Vertex Pharmaceuticals’s revenue for the quarter was up 13.3% on a year-over-year basis. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on VRTX shares. Barclays boosted their target price on shares of Vertex Pharmaceuticals from $446.00 to $472.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Piper Sandler boosted their target price on shares of Vertex Pharmaceuticals from $450.00 to $456.00 and gave the company an “overweight” rating in a research report on Tuesday. Maxim Group downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Oppenheimer restated an “outperform” rating and set a $500.00 target price on shares of Vertex Pharmaceuticals in a research report on Monday, April 15th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a report on Tuesday. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $432.18.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Jeffrey M. Leiden sold 2,656 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $419.51, for a total value of $1,114,218.56. Following the completion of the sale, the chairman now directly owns 27,644 shares of the company’s stock, valued at $11,596,934.44. The disclosure for this sale can be found here. Insiders sold 12,381 shares of company stock valued at $5,203,249 in the last three months. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.